ex99_2.htm

Chembio Reports Third Quarter Results

Conference Call Begins at 11:30 a.m. Eastern Time, November 2nd

MEDFORD, N.Y (November 2, 2007) – Chembio Diagnostics, Inc. (OTC/BB: CEMI) today reported financial results for the three and nine months ended September 30, 2007.

Total revenues for the third quarter of 2007 were $2.31 million, a 127% increase compared with total revenues for the third quarter of 2006 of $1.02 million. The net loss attributable to common stockholders for the third quarter of 2007 was $1.01 million, or $0.07 per share, compared with the net loss attributable to common stockholders for the third quarter of 2006 of $2.33 million, or $0.21 per share. These net loss figures include $363,000 and $760,000, respectively, related to dividends (which includes a beneficial conversion feature in the 2006 period of $539,000) on the Company’s convertible preferred stock, of which $363,000 and $221,000, respectively, were non-cash dividends paid in-common stock.

Total revenues for the first nine months of 2007 were $6.85 million, a 76% increase compared with total revenues for the first nine months of 2006 of $3.89 million. The net loss attributable to common stockholders for the first nine months of 2007 was $3.08 million, or $0.24 per share, compared with the net loss attributable to common stockholders for the first nine months of 2006 of $5.61 million, or $0.56 per share. These net loss figures include $1.07 million and $1.64 million, respectively, related to dividends (which includes a beneficial conversion feature in the 2006 period of $1.00 million) on the Company’s convertible preferred stock, of which $1.01 million and $502,000, respectively, were non-cash dividends paid in-common stock.

Growth in revenues during the third quarter and first nine months of 2007 was attributable to higher sales of the Company's rapid HIV products, which increased 261% and 201%, respectively, compared with the prior-year periods, due primarily to sales growth in Africa and North America.

Net sales to Africa increased by $815,000 to $1.31 million during the quarter, primarily due to sales placed by the Partnership For Supply Chain Management, the consortium with which the Company signed a contract during the second quarter of this year and which, as expected, is increasingly centralizing procurements made with the President’s Emergency Plan for AIDS Relief funds. North American sales increased $620,000 to $750,000 in the quarter, largely due to the launch of the Company’s HIV tests in the U.S. in February 2007 by marketing partner Inverness Medical Innovations. Inverness markets the Company’s two rapid HIV tests under the Clearview® label. Through September 30, 2007, only one of those tests, Clearview® HIV 1/2 STAT PAK, was “CLIA-waived” (allowing sales into public health clinics, for example), and this product represents almost all sales to Inverness for the reported periods. Chembio recently received a CLIA waiver for its HIV barrel product, marketed as Complete HIV 1/2 by Inverness. As a result, the Company anticipates sales of this product to increase in the coming quarters.

Gross profit for the third quarter of 2007 increased to $1.0 million, or 42.5% of total revenues, compared with gross profit of $187,000, or 18.4% of total revenues, for the third quarter of 2006. Gross profit on product sales for the third quarter of 2007 increased to $830,000, or 38.4%, compared with gross profit on product sales of $111,000, or 11.8%, for the third quarter of 2006. The loss from operations for the third quarter of 2007 decreased to $673,000 from $1.24 million in the prior-year quarter.

Gross profit for the first nine months of 2007 increased to $2.64 million, or 38.4% of total revenues, compared with gross profit of $1.19 million, or 30.5% of total revenues, for the first nine months of 2006. Gross profit on product sales for the first nine months of 2007 increased to $2.39 million, or 36.1%, compared with gross profit on product sales of $0.98 million, or 26.5%, for the first nine months of 2006. The loss from operations for the first nine months of 2007 decreased to $2.24 million from $3.62 million for the first nine months of 2006.

Several important milestones were achieved during the third quarter of 2007, including:

Financial Results– Revenues for the first nine months of 2007 have already exceeded full-year 2006 revenues. The Company has improved gross margin on product sales to 38.4% and 36.1% for the three and nine months ended September 30, 2007, respectively. The expanded gross margin is attributable to higher average selling prices of the Company’s HIV tests in the U.S., as well as to improved operating efficiencies that are beginning to be realized through the ERP production planning and cost-management system Chembio installed last year.

Dual Platform Technology Business Development–Since the latter half of the second quarter, the Company has entered into five externally funded research and development or feasibility agreements with clinical diagnostics, life science, companion animal, academic and government-affiliated public health entities, all related to potential applications for point-of-care tests employing Chembio’s Dual Path Platform (DPP™) technology. These agreements represent total financial commitments of $600,000 (approximately $200,000 of which was earned in the second and third quarters of 2007). Results from these feasibility studies, as well as from the Company’s internal research and development activities, are confirming the potential of this platform technology for a broad range of point-of-care/point-of-use diagnostics.

DPP HIV 1/2 – The Company completed a prototype of its DPP™ HIV 1/2 test for whole blood, serum and plasma, and is conducting studies with various components to optimize oral fluid features. Chembio is considering various regulatory pathways and potential marketing and distribution strategies for this product.

DPP Syphilis – Chembio entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Centers for Disease Control and Prevention (CDC) in November 2006. The goal of the CRADA was to develop a DPP™ multiplex test that could be used both to screen for antibodies to Syphilis (known as treponomal) and to confirm them (known as non-treponomal). During the third quarter the Company completed validation work for the treponomal screening test and submitted several thousand treponomal tests for use in a large overseas CDC study; Chembio is awaiting results of the study.

Reader Technologies – The Company has made significant progress in employing proprietary reflectance and fluorescence reader devices that can measure, record and report results of DPP™ tests with greater consistency than interpretation through visual observation. These readers are being customized for its DPP™ platform and will be further customized, as needed, for specific DPP™ applications. This will be particularly important with the development of multiplex tests on DPP™, which we believe to be a significant advantage of DPP™ due to the independently-controlled, direct, even and simultaneous delivery of sample material to the test zone area that is unique to DPP™. The DPP™ technology demonstrates much improved multiplexing results and membrane clearance compared with conventional single path lateral flow technologies. This substantially increases the utility and accuracy of readers. Chembio has made significant progress in adapting these reading instruments to DPP™, using both colored and fluorescent labels. In addition, the Company has entered into a collaboration with a development-stage company that has a patent-pending technology believed to increase detection levels by using that company’s unique fluorescence labeling methodology.

Foreign DPP Patent Filings – In support of Chembio’s strategy to build its pipeline of DPP™ product-development opportunities, the Company filed for protection of its DPP™ intellectual property in several foreign jurisdictions where it believes patent protection is warranted, including portions of Europe, Asia and South America.

CLIA Waiver– Earlier this week the Company received a CLIA waiver for its HIV barrel product. A CLIA waiver greatly expands a product’s potential U.S. market opportunity from sites with highly regulated certification and oversight (i.e., reference laboratories and hospital laboratories) to include venues where point-of-care testing is particularly beneficial (i.e., emergency rooms, physician offices and public health clinics). There are approximately 189,000 testing sites across the U.S. that can use tests that are CLIA-waived.

ISO 13.485 Certification– During the third quarter Chembio received its ISO 13.485 certification, underscoring the quality of Chembio’s systems and demonstrating its ability to produce point-of-care diagnostics in accordance with widely accepted global quality standards. ISO 13.485 is the quality system most recognized globally, including throughout the European Union for products seeking a CE marking. Chembio has engaged a European Notified Body in connection with its plans to obtain a CE marking for certain of its products.

Lawrence Siebert, Chairman and President of Chembio, commented, “We are pleased with our progress during the third quarter, as we achieved exceptionally strong revenue growth, continued to improve our gross margins, controlled our operating expenses and made significant headway in developing significant new DPP™-related product opportunities.”

CONFERENCE CALL

Chembio has scheduled a conference call and webcast for 11:30 a.m. Eastern time on Friday November 2, 2007. Participants may access the call by dialing (877) 407-9205 in the U.S. or (201) 689-8054 outside the U.S. The conference call may also be accessed via the internet at http://www.vcall.com/IC/CEPage.asp?ID=122663. An archive of the webcast will be available for 90 days on the Company’s website at www.chembio.com.

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of proprietary rapid diagnostic tests, participates in the growing $5 billion point-of-care (POC) testing market. Chembio’s two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Inverness Medical Innovations, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007, Chembio received a U.S. patent for its Dual Path Platform (DPP™) technology which has significant advantages over currently available lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP™. Headquartered in Medford, NY with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals for its products in a timely manner and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof, or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

[Tables to Follow]

Company Contact: Investor Relations Contacts:

Chembio Diagnostics, Inc. Lippert/Heilshorn & Associates, Inc.

Matty Arce

Anne Marie Fields (afields@lhai.com)

631-924-1135 ext 123 (212) 838-3777

www.chembio.com Bruce Voss (bvoss@lhai.com)

(310) 691-7100

www.lhai.com

Chembio Diagnostics, Inc.
Summary of Results of Operations

	For the three months ended						For the nine months ended
	September 30, 2007			September 30, 2006			September 30, 2007			September 30, 2006
Total Revenues	$	2,313,537		$	1,018,190		$	6,854,631		$	3,893,093

Gross Profit		985,009			187,371			2,636,728			1,187,344

Operating Loss		(672,709	)		(1,240,474	)		(2,238,444	)		(3,615,740	)

Net Loss		(648,514	)		(1,573,986	)		(2,003,176	)		(3,965,076	)

Preferred Dividends and Beneficial Conversion Feature		362,959			759,469			1,073,837			1,643,763

Net Loss Attributable to Common Stockholders	$	(1,011,473	)	$	(2,333,455	)	$	(3,077,013	)	$	(5,608,839	)

Loss per share	$	(0.07	)	$	(0.21	)	$	(0.24	)	$	(0.56	)

Chembio Diagnostics, Inc.
Summary of Balance Sheet

	September 30, 2007			December 31, 2006
CURRENT ASSETS:
Cash	$	2,255,307		$	4,290,386
Other current assets		2,876,408			2,663,282
TOTAL CURRENT ASSETS		5,131,715			6,953,668

NET FIXED ASSETS		652,658			603,603

OTHER ASSETS		357,362			349,306

	$	6,141,735		$	7,906,577

TOTAL CURRENT LIABILITIES	$	1,694,416		$	1,840,435

TOTAL OTHER LIABILITIES		245,284			456,758

TOTAL LIABILITIES		1,939,700			2,297,193

PREFERRED STOCK -Series C		6,837,479			6,549,191

TOTAL STOCKHOLDERS’ EQUITY (DEFICIENCY)		(2,635,444	)		(939,807	)

	$	6,141,735		$	7,906,577

# # #